Skeletal Disease Contributes Substantially to Morbidity and Mortality in Patients with Lung Cancer
Author:
- 1 July 2009
- journal article
- review article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 10 (4) , 223-229
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous BisphosphonatesJournal of Bone and Mineral Research, 2008
- Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast ActivityJournal of Thoracic Oncology, 2008
- Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical PerspectivesThe Oncologist, 2008
- PD6-3-8: Skeletal morbidity and zoledronic acid benefits in patients with bone metastases from non-small cell lung cancerJournal of Thoracic Oncology, 2007
- Skeletal metastases in non-small cell lung cancer: A retrospective studyLung Cancer, 2007
- Impact of Skeletal Complications on Total Medical Care Costs among Patients with Bone Metastases of Lung CancerJournal of Thoracic Oncology, 2006
- Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic AcidJournal of Clinical Oncology, 2005
- Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer ModelClinical Cancer Research, 2004